Asian Journal of Pharmaceutical Research and Development
Advanced Herbal Approaches to Diabetes and Metabolic Disorders: Current Status and Future Prospects
Par Ajita S. Kesharwani, Palak Ghanshyam Rahangdale, Rashmi Khanijau et 2 autres.
Contenu en anglais
Résumé
Diabetes and related metabolic issues are major health problems around the world. In many cases, blood sugar is not well controlled. Insulin may not work as it should. Levels of fats in the blood can also become abnormal. Over time, oxidative stress builds up. Mild inflammation tends to continue too. Many people do benefit from common drug therapy. Even so, some medicines lead to side effects. In other cases, the response is not strong enough. Because these conditions come from more than one cause, interest in herbal options has grown. Researchers are examining plant compounds as possible supportive choices. This review explains the current status of herbal approaches. It also looks at what might happen next. Topics include the main chemicals found in these plants. It covers possible ways those chemicals may act in the body. It then summarizes what clinical studies report and how ready the evidence is for everyday use. The review also groups plant chemical types into several categories. The review covers both lab work and tests in people. It looks at medicinal plants as well as specific plant chemicals. Absorption is a key focus. Safety is discussed too, including side risks and possible clashes between herbs and drugs. Product strength is another concern. Extracts can differ a lot between one batch and the next.New ways to deliver these compounds are also included. The text mentions nanoparticles, phytosomes, liposomes, and other carriers. These systems may improve water solubility. They may also help compounds stay stable. Better uptake in the body is another point. If uptake improves, the effects in treatment could be stronger.For future work, the authors highlight multi target strategies. They also bring up metabolomics and plans that can be adjusted for each person. They suggest that artificial intelligence could aid trial design and data review. They emphasize the need for products that stay consistent and are well standardized. More toxicology studies are needed. More work on pharmacokinetics is also important. Finally, clinical trials should be planned better so herbal options for metabolic problems can be judged with solid evidence.



